Search

1. People Power: Training Canada’s Next-Gen HQP in Regenerative Medicine
   ...in the the age of market-authorized gene and cell therapies. How prepared is Canada when it comes to having enough highly qualified professionals (HQP) to support a competitive, home-grown industry?...
2. Supporting Canada’s Home-Grown Innovation
   ...that many big ideas are said to die in the “valley of death” between early and late-stage research. Thankfully, one of Canada’s hidden gems of cell-based technology commercialization offers a...
3. Back to Basic
   By Lisa Willemse; co-published at www.medium*]}*.com/the-expression Today’s research environment has a strong emphasis on translation to new technologies and treatments. But we wouldn’t be here without basic research and tomorrow’s...
4. How a blood-loving parasite gave us a better understanding of Rett Syndrome
   By Lisa Willemse; co-published at www.medium*]}*.com/the-expression On the surface, there is very little to connect the parasite responsible for Chagas disease with Rett Syndrome, an X-linked neurodegenerative disorder. One is...
5. Thinking Out of the Big-Box for Cancer Treatment
   ...will also help drive down costs and increase the speed of development.” For more information on ongoing BioCanRx clinical trials and other types of research, go to www.biocanrx.com. Photo: OHRI...
6. Partnerships & Industry Offers
   OIRM is committed to supporting scientists in Ontario’s regenerative medicine community. As part of that commitment, we have developed our Partnership Program to help OIRM investigators and trainees stretch their...
7. Program Announcements
   ...by Hongkui Deng of Peking University. Michael May of CCRM will be the commercialization lead bringing together key regenerative medicine partners from CCRM’s Industry Consortium. For more information on this...
8. OIRM Awards almost $3M in research funding for 2019-2020
   ...investigators and their patients as we build a healthier future for Ontario, Canada, and the world.   For more information: Krista Lamb, Director, Communications and Marketing, OIRM 647-403-5627 – krista.lamb@oirm.ca...
9. Ontario biotechs in good company with CCRM’s Industry Consortium
   ...expansion of blood stem cells for transplantation to treat leukemia, among many other examples.   Indeed, without the commercialization component, many research discoveries would simply wither and die. This is...
10. Erik Suuronen
    Profile: Scientist, University of Ottawa Heart Institute Department: Surgery, University of Ottawa Research Interests: Coronary artery disease is the most important killer of Canadians. Despite major advances in therapy, there...